Central Nervous System Treatment Market

Central Nervous System Treatment Market by Disease Type (Neurovascular Diseases, Neurodegenerative Diseases, Mental Health, CNS Trauma, Others), by Drug Class (Antidepressants, Analgesics, Anesthetics, Anticonvulsants & Antiseizures, Anti-Parkinsonian Agents, Anxiolytics & Sedatives, CNS Stimulants, Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) - Global Outlook & Forecast 2022-2030

GR - 817133 Category: Pharmaceuticals

Number of pages: 100 | Report Format: PDF | Published date: December 06, 2022

Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030

Central Nervous System Treatment Market Scope

Report Attribute	Details
Market size value in 2021	US$ 87.23 billion
Revenue forecast in 2030	US$ 191.01 billion
Growth Rate	CAGR of 9.10% from 2022 to 2030
Base year for estimation	2021
Forecast period	2022-2030
Segments covered	Disease Type, Drug Class, Distribution Channel, and Region.
Regional scope	North America, Europe, Asia Pacific, and the Rest of the World (ROW)

Report Overview

The global central nervous system treatment market was pegged at US$ 87.23 billion in 2021 and is expected to witness a CAGR of 9.10% during the forecast period from 2022 to 2030.

Market Fundamentals

The central nervous system (CNS) is the largest part of the nervous system consisting primarily of the brain and spinal cord. CNS diseases are diverse, occurring at every life stage with varying severity. It consists of a broad range of conditions ranging from pain & addiction to neurodegeneration & mood disorders. There are many different types of agents that have an effect on the CNS, including anesthetics, anticonvulsants, antiparkinsonian agents, CNS stimulants, muscle relaxants, narcotic analgesics, nonnarcotic analgesics, and sedatives.

[873894]

Market Dynamics

The global central nervous system treatment market is mainly driven by the increasing prevalence of neurological disorders, and a growing geriatric population that is more vulnerable to central nervous diseases. Additionally, increasing investment in the research and development of novel drugs, rising clinical trials for central nervous drugs, and a growing number of regulatory-approved drugs is boosting the global central nervous system treatment market. Moreover, increasing pipeline drugs, the introduction of novel diagnostic technologies, and promising pipeline drugs are fueling the global central nervous system market. However, high spending and investments in research and development are restraining the global central nervous system market growth.

Market Ecosystem

The global central nervous system treatment market has been analyzed from four perspectives: disease type, drug class, distribution channel, and region.

Central Nervous System Treatment Market by Diseases Type

[1231233]

Based on diseases type, the global central nervous system treatment market has been segmented into neurovascular diseases (hemorrhagic stroke, ischemic stroke, and others), neurodegenerative diseases (degenerative diseases, Alzheimer’s disease, Parkinson’s disease, and others), mental health, CNS Trauma, and others. Neurodegenerative diseases lead the global central nervous system treatment market owing to the increasing prevalence of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and spine degenerative diseases. Additionally, the growing geriatric population and increasing mental health cases due to changes in lifestyle, stress, and anxiety are contributing to the growth of the neurodegenerative diseases segment. In June 2022, the World Health Organization stated that more people worldwide are becoming disabled and dying from Parkinson's disease (PD), than from any other neurological condition. In the last 25 years, the prevalence of Parkinson’s disease has doubled. According to the World Health Organization, in 2019 there were over 8.5 million people worldwide with Parkinson’s disease. Parkinson's disease caused 329,000 deaths in 2019, an increase of over 100% since 2000, and 5.8 million disability-adjusted life years, an increase of 81% since 2000.

Central Nervous System Treatment Market by Drug Class

Based on drug class, the global central nervous system treatment market is segmented into antidepressants, analgesics, anesthetics, anticonvulsants & antiseizure, anti-parkinsonian agents, anxiolytics & sedatives, CNS stimulants, and others. The antidepressants segment is leading the global central nervous system treatment market owing to high efficacy & therapeutic effects and growing demand for antidepressant drugs for treating CNS diseases. Additionally, promising pipeline drugs and increasing research & development for antidepressant drugs are contributing to the growth of the antidepressants segment.

Central Nervous System Treatment Market by Distribution Channel

Based on distribution channel, the global central nervous system treatment market has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is leading the global central nervous system treatment market owing to the increasing prevalence of neurological diseases, increasing patient footfall for diagnosis & treatment, and increasing adoption of treatment technologies in hospitals.

Central Nervous System Treatment Market by Region

Based on region, the global central nervous system treatment market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the global central nervous system treatment market in terms of revenue share. The prominence of North America in the global market can be attributed to the increasing adoption of novel treatments, and the high prevalence of neurological disorders such as Parkinson's disease, Alzheimer’s disease, and others. Additionally, favorable reimbursement policies, developed infrastructure, and technological advancement are also driving the North America central nervous system treatment market. Whereas, Asia Pacific is expected to show the highest growth during the forecast period owing to the rapidly growing patient pool and developing healthcare infrastructure.

Competitive Landscape

Some prominent players operating in the global central nervous system treatment market are

AstraZeneca plc
Biogen Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Johnson & Johnson Inc.
Novartis AG
Otsuka Pharmaceutical Co. Ltd.
Pfizer Inc.
Sanofi SA
Teva Pharmaceutical Industries Ltd.

Strategic Developments

In June 2021, Biogen Inc. received the US Food and Drug Administration approval for Aduhelm for the treatment of Alzheimer's disease. Aduhelm is the first-ever Alzheimer's disease treatment approved since 2003, and the first therapy that targets the disease's fundamental pathophysiology.
In July 2022, The US Food and Drug Administration recognized Biogen's novel therapeutic drug application and approve a priority review of tofersen for the hereditary form of Amyotrophic Lateral Sclerosis. Amyotrophic lateral sclerosis (ALS) is a rare, progressive, and fatal neurodegenerative disease that results in the damage of motor neurons in the brain and spinal cord that control voluntary muscle movement.

Frequently Asked Questions About This Report

North America and Asia Pacific are the key growth regions in the global central nervous system treatment market.

The increasing prevalence of neurological disease, increasing investment in research & development, and the growing geriatric population are driving the growth of the global central nervous system treatment market.

The expected CAGR for the global central nervous system treatment market is 9.1% during the forecast period from 2022 to 2030.

The estimated market size of the global central nervous system treatment market is US$ 191.02 billion in 2030.

AstraZeneca Plc, Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Inc., Novartis AG, Otsuka Pharmaceutical Co. Ltd, Pfizer Inc., Shire plc, Sanofi SA, Merck KGaA and Teva Pharmaceutical Industries Ltd. among others.

Table of Content

INTRODUCTION
1. Market Ecosystem
2. Timeline Under Consideration
  1. Historical Years – 2020
  2. Base Year – 2021
  3. Forecasted Years – 2022 to 2030
3. Currency Used in the Report
RESEARCH METHODOLOGY
1. Research Approach
2. Data Collection Methodology
3. Data Sources
  1. Secondary Sources
  2. Primary Sources
4. Market Estimation Approach
  1. Bottom Up
  2. Top Down
5. Market Forecasting Model
6. Limitations and Assumptions
PREMIUM INSIGHTS
1. Current Market Trends (COVID-19 Perspective)
2. Key Players & Competitive Positioning (2021)
MARKET DYNAMICS
1. Drivers
2. Restraints/Challenges
3. Opportunities
GLOBAL CENTRAL NERVOUS SYSTEM TREATMENT MARKET - ANALYSIS & FORECAST, BY DISEASE TYPE
1. Neurovascular Diseases
  1. Hemorrhagic Stroke
  2. Ischemic Stroke
  3. Others
2. Neurodegenerative Diseases
  1. Degenerative Diseases
  2. Alzheimer’s Diseases
  3. Parkinson’s Diseases
  4. Others
3. Mental Health
  1. Mood Disorders
  2. Psychotic Disorders
  3. Anxiety Disorders
  4. Others
4. CNS Trauma
5. Others
GLOBAL CENTRAL NERVOUS SYSTEM TREATMENT MARKET - ANALYSIS & FORECAST, BY DRUG CLASS
1. Antidepressants
2. Analgesics
3. Anesthetics
4. Anticonvulsants & Antiseizures
5. Anti-Parkinsonian Agents
6. Anxiolytics & Sedatives
7. CNS Stimulants
8. Others
GLOBAL CENTRAL NERVOUS SYSTEM TREATMENT MARKET - ANALYSIS & FORECAST, BY DISTRUBUTION CHANNEL
1. Hospital Pharmacy
2. Retail Pharmacy
3. Online Pharmacy
GLOBAL CENTRAL NERVOUS SYSTEM TREATMENT MARKET - ANALYSIS & FORECAST, BY REGION
1. North America Central Nervous System Treatment Market
  1. North America Central Nervous System Treatment Market, by Disease Type
  2. North America Central Nervous System Treatment Market, by Drug Class
  3. North America Central Nervous System Treatment Market, by Distribution Channel
  4. North America Central Nervous System Treatment Market, by Country
    1. U.S.
      1. U.S. Central Nervous System Treatment Market, by Disease Type
      2. U.S. Central Nervous System Treatment Market, by Drug Class
      3. U.S. Central Nervous System Treatment Market, by Distribution Channel
    2. Canada
      1. Canada Central Nervous System Treatment Market, by Disease Type
      2. Canada Central Nervous System Treatment Market, by Drug Class
      3. Canada Central Nervous System Treatment Market, by Distribution Channel
2. Europe Central Nervous System Treatment Market
  1. Europe Central Nervous System Treatment Market, by Disease Type
  2. Europe Central Nervous System Treatment Market, by Drug Class
  3. Europe Central Nervous System Treatment Market, by Distribution Channel
  4. Europe Central Nervous System Treatment Market, by Country/Region
    1. Germany
      1. Germany Central Nervous System Treatment Market, by Disease Type
      2. Germany Central Nervous System Treatment Market, by Drug Class
      3. Germany Central Nervous System Treatment Market, by Distribution Channel
    2. U.K.
      1. U.K. Central Nervous System Treatment Market, by Disease Type
      2. U.K. Central Nervous System Treatment Market, by Drug Class
      3. U.K. Central Nervous System Treatment Market, by Distribution Channel
    3. Spain
      1. Spain Central Nervous System Treatment Market, by Disease Type
      2. Spain Central Nervous System Treatment Market, by Drug Class
      3. Spain Central Nervous System Treatment Market, by Distribution Channel
    4. Italy
      1. Italy Central Nervous System Treatment Market, by Disease Type
      2. Italy Central Nervous System Treatment Market, by Drug Class
      3. Italy Central Nervous System Treatment Market, by Distribution Channel
    5. France
      1. France Central Nervous System Treatment Market, by Disease Type
      2. France Central Nervous System Treatment Market, by Drug Class
      3. France Central Nervous System Treatment Market, by Distribution Channel
    6. Rest of Europe
      1. Rest of Europe Central Nervous System Treatment Market, by Disease Type
      2. Rest of Europe Central Nervous System Treatment Market, by Drug Class
      3. Rest of Europe Central Nervous System Treatment Market, by Distribution Channel
3. Asia Pacific Central Nervous System Treatment Market
  1. Asia Pacific Central Nervous System Treatment Market, by Disease Type
  2. Asia Pacific Central Nervous System Treatment Market, by Drug Class
  3. Asia Pacific Central Nervous System Treatment Market, by Distribution Channel
  4. Asia Pacific Central Nervous System Treatment Market, by Country/Region
    1. China
      1. China Central Nervous System Treatment Market, by Disease Type
      2. China Central Nervous System Treatment Market, by Drug Class
      3. China Central Nervous System Treatment Market, by Distribution Channel
    2. Japan
      1. Japan Central Nervous System Treatment Market, by Disease Type
      2. Japan Central Nervous System Treatment Market, by Drug Class
      3. Japan Central Nervous System Treatment Market, by Distribution Channel
    3. India
      1. India Central Nervous System Treatment Market, by Disease Type
      2. India Central Nervous System Treatment Market, by Drug Class
      3. India Central Nervous System Treatment Market, by Distribution Channel
    4. South Korea
      1. South Korea Central Nervous System Treatment Market, by Disease Type
      2. South Korea Central Nervous System Treatment Market, by Drug Class
      3. South Korea Central Nervous System Treatment Market, by Distribution Channel
    5. Australia
      1. Australia Central Nervous System Treatment Market, by Disease Type
      2. Australia Central Nervous System Treatment Market, by Drug Class
      3. Australia Central Nervous System Treatment Market, by Distribution Channel
    6. Rest of Asia Pacific
      1. Rest of Asia Pacific Central Nervous System Treatment Market, by Disease Type
      2. Rest of Asia Pacific Central Nervous System Treatment Market, by Drug Class
      3. Rest of Asia Pacific Central Nervous System Treatment Market, by Distribution Channel
4. Rest of the World Central Nervous System Treatment Market
  1. Rest of the World Central Nervous System Treatment Market, By Region
  2. Rest of the World Central Nervous System Treatment Market, by Disease Type
  3. Rest of the World Central Nervous System Treatment Market, by Drug Class
  4. Rest of the World Central Nervous System Treatment Market, by Distribution Channel
    1. Latin America
      1. Latin America Central Nervous System Treatment Market, by Disease Type
      2. Latin America Central Nervous System Treatment Market, by Drug Class
      3. Latin America Central Nervous System Treatment Market, by Distribution Channel
    2. Middle East & Africa
      1. Middle East & Africa Central Nervous System Treatment Market, by Disease Type
      2. Middle East & Africa Central Nervous System Treatment Market, by Drug Class
      3. Middle East & Africa Central Nervous System Treatment Market, by Distribution Channel
COMPANY PROFILES
1. AstraZeneca Plc
  1. Business Snapshot
  2. Products Offered
  3. Financial Details*
  4. Strategic Developments
2. Biogen Inc.
3. Eli Lilly and Company
4. F. Hoffmann-La Roche Ltd.
5. Johnson & Johnson Inc.
6. Novartis AG
7. Otsuka Pharmaceutical Co. Ltd
8. Pfizer Inc.
9. Shire plc
10. Sanofi SA
11. Merck KGaA
12. Teva Pharmaceutical Industries Ltd.

*Insights on financial performance are subject to the availability of information in the public domain

Single User License

Multi User License

Enterprise User License

$4,750.00

What are the significant driving and restraining factors for the Central Nervous System Treatment Market?
Who are the leading companies in the market?
Where can you find the updates on recent developments by market players?
When is the right time to get discounts on complete market reports?
Why to invest in the Central Nervous System Treatment Market?
How to improve your organizational performance?
How to shift customers towards your brand?

Ask For Customization Check Discount Inquire Before Buying

Recommended Reports